Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Vincristine is named as an intervention in 42 current clinical trials in our China, USA, UK, Ireland and India registers. 20 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Celgene (4). The most-studied condition is Diffuse Large B-Cell Lymphoma.

Trials by status

Recruiting2048%
Not yet open512%
Active, closed1638%
By invitation12%

Trials by phase

Phase 31945%
Phase 21433%
Phase 1/2512%
Phase 2/325%
Phase 112%
Not applicable12%

Clinical trials of Vincristine

42 trials

Study	Phase	Status	Lead sponsor	Registers
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) NCT01704716 · Neuroblastoma	Phase 3	Recruiting	St. Anna Kinderkrebsforschung	Ireland
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma NCT04043494 · Lymphoblastic Lymphoma, Childhood	Phase 3	Recruiting	University Hospital Muenster	Ireland, China
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) NCT04638790 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma, Adult	Phase 3	Recruiting	State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia	India
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma NCT06091254 · ClinicalTrials.gov ↗ · Follicular Lymphoma (FL)	Phase 3	Recruiting	Regeneron Pharmaceuticals	UK, USA
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma NCT06091865 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma (DLBCL)	Phase 3	Recruiting	Regeneron Pharmaceuticals	Ireland, UK, USA
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) NCT06717347 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) NCT06911502 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Phase 3	Recruiting	Celgene	UK, USA, India, China
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) NCT07634471 · Follicular Lymphoma	Phase 2/3	Recruiting	Merck Sharp & Dohme LLC	USA, China
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage NCT04440267 · ClinicalTrials.gov ↗ · Acute Leukemia of Ambiguous Lineage	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Modified CV Regimen in Optic Pathway Glioma NCT05278715 · ClinicalTrials.gov ↗ · Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma	Phase 2	Recruiting	Beijing Sanbo Brain Hospital	China
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia NCT05660473 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL NCT06387121 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. NCT06514313 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma	Phase 2	Recruiting	Yizhuo Zhang	China
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial NCT06700798 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma(MZL)	Phase 2	Recruiting	Fei Li	China
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma NCT06704555 · ClinicalTrials.gov ↗ · Follicular Lymphoma	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL NCT07493148 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2	Recruiting	Ou Bai, MD/PHD	China
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement NCT04432714 · ClinicalTrials.gov ↗ · DLBCL, Untreated, MYC Gene Rearrangement	Phase 1/2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma NCT04625907 · ClinicalTrials.gov ↗ · Rhabdomyosarcoma	Phase 1/2	Recruiting	University of Birmingham	Ireland
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies NCT06564038 · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis NCT07431060 · ClinicalTrials.gov ↗ · Langerhans Cell Histiocytosis (LCH)	Not applicable	Recruiting	West China Second University Hospital	China
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma NCT07719855 · ClinicalTrials.gov ↗ · Follicular Lymphoma ( FL)	Phase 3	Not yet open	Ruijin Hospital	China
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) NCT07712588 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 2/3	Not yet open	Dizal Pharmaceuticals	China
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients NCT07301138 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Phase 2	Not yet open	Ruijin Hospital	China
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma NCT07535762 · ClinicalTrials.gov ↗ · Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)	Phase 2	Not yet open	Shanghai Jiao Tong University School of Medicine	China
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma NCT07535710 · ClinicalTrials.gov ↗ · Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome	Phase 1/2	Not yet open	Shanghai Jiao Tong University School of Medicine	China
AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH NCT05678933 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma Targeted Therapy	Phase 3	By invitation	Tianjin Medical University Cancer Institute and Hospital	China
Paediatric Hepatic International Tumour Trial NCT03017326 · ClinicalTrials.gov ↗ · Hepatoblastoma, Carcinoma, Hepatocellular	Phase 3	Active, closed	University of Birmingham	Ireland
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia NCT03589326 · ClinicalTrials.gov ↗ · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	Phase 3	Active, closed	Takeda	USA, China
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) NCT04529772 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Acerta Pharma BV	USA, India, China
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients NCT04824092 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma	Phase 3	Active, closed	Incyte Corporation	Ireland, UK, USA
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma NCT05371093 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) NCT05578976 · Diffuse Large B-Cell Lymphoma	Phase 3	Active, closed	Genmab	UK, USA, China
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma NCT05605899 · High-risk Large B-cell Lymphoma (LBCL)	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma NCT06097364 · ClinicalTrials.gov ↗ · Follicular Lymphoma (FL)	Phase 3	Active, closed	Regeneron Pharmaceuticals	UK, USA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma NCT06191744 · ClinicalTrials.gov ↗ · Follicular Lymphoma (FL)	Phase 3	Active, closed	Genmab	UK, USA, China
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma NCT06356129 · ClinicalTrials.gov ↗ · Large B-cell Lymphoma	Phase 3	Active, closed	Celgene	USA, India, China
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) NCT03407144 · Hodgkin Lymphoma	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma NCT04067037 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma	Phase 2	Active, closed	Henan Cancer Hospital	China
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma NCT04980222 · Lymphoma	Phase 2	Active, closed	Hoffmann-La Roche	USA
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma NCT06425302 · ClinicalTrials.gov ↗ · Lymphoma, Follicular	Phase 2	Active, closed	Celgene	UK, USA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma NCT05201248 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma	Phase 1/2	Active, closed	Genmab	China
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma NCT04884035 · ClinicalTrials.gov ↗ · Lymphoma, B-Cell	Phase 1	Active, closed	Celgene	USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Vincristine across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

1 single-substance product containing Vincristine on the HPRA medicines list.

Vincristine Sulfate 1mg/ml Solution for Injection or InfusionPfizer Healthcare Ireland Unlimited Company · PA0822/232/001 · Marketed

All 1 Irish product →

Supply shortages

No entry for Vincristine in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Vincristine

45 conditions

Diffuse Large B-Cell Lymphoma3 Follicular Lymphoma (FL)3 Follicular Lymphoma3 Large B-cell Lymphoma2 Diffuse Large B-Cell Lymphoma (DLBCL)2Precursor Cell Lymphoblastic Leukemia-Lymphoma2Lymphoblastic Lymphoma, Childhood1Neuroblastoma1Rhabdomyosarcoma1Diffuse Large B-cell Lymphoma1 Diffuse Large B-cell Lymphoma (DLBCL)1Hepatoblastoma1

All 45 conditions

Condition (as registered)	Trials
Diffuse Large B-Cell Lymphoma	3
Follicular Lymphoma (FL)	3
Follicular Lymphoma	3
Large B-cell Lymphoma	2
Diffuse Large B-Cell Lymphoma (DLBCL)	2
Precursor Cell Lymphoblastic Leukemia-Lymphoma	2
Lymphoblastic Lymphoma, Childhood	1
Neuroblastoma	1
Rhabdomyosarcoma	1
Diffuse Large B-cell Lymphoma	1
Diffuse Large B-cell Lymphoma (DLBCL)	1
Hepatoblastoma	1
Carcinoma, Hepatocellular	1
Hodgkin Lymphoma	1
Chronic Lymphocytic Leukaemia	1
Small Lymphocytic Lymphoma	1
Mantle-cell Lymphoma	1
High-risk Large B-cell Lymphoma (LBCL)	1
Relapsed/Refractory Follicular Lymphoma	1
Lymphoma, Follicular	1
Lymphoma	1
Lymphoma, B-Cell	1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)	1
Hodgkin Lymphoma, Adult	1
B-Cell Non-Hodgkin Lymphoma	1
Peripheral T-cell Lymphoma Targeted Therapy	1
Follicular Lymphoma ( FL)	1
Acute Leukemia of Ambiguous Lineage	1
Langerhans Cell Histiocytosis (LCH)	1
Acute Lymphoblastic Leukemia	1
Classical Hodgkin Lymphoma	1
DLBCL	1
Untreated	1
MYC Gene Rearrangement	1
Soft Tissue Sarcoma	1
Optic Glioma	1
Pediatric Brain Tumor, Optic Nerve Glioma	1
Peripheral T-Cell Lymphoma (PTCL NOS)	1
Nodal T-follicular Helper Cell Lymphoma	1
Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)	1
Marginal Zone Lymphoma(MZL)	1
Cutaneous T-Cell Lymphoma Refractory	1
Cutaneous T-Cell Lymphoma, Relapsed	1
Sezary Syndrome	1
Cutaneous T Cell Lymphoma (CTCL)	1

By country register

Register	Trials	Recruiting
Clinical trials in China	28	15
Clinical trials in USA	19	6
Clinical trials in UK	12	4
Clinical trials in Ireland	6	4
Clinical trials in India	4	2

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Vincristine trials

How many clinical trials are testing Vincristine?

42 current trials in our China, USA, UK, Ireland and India registers name Vincristine as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Vincristine trials recruiting patients?

Yes. 20 of the 42 trials are recruiting: 15 with sites in China, 6 with sites in USA, 4 with sites in UK, 4 with sites in Ireland and 2 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Vincristine clinical trials?

Celgene (4), Regeneron Pharmaceuticals (3), Genmab (3) and Merck Sharp & Dohme LLC (3), among 26 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Vincristine licensed in Ireland?

Yes. The HPRA medicines list includes 1 single-substance product containing Vincristine, for example Vincristine Sulfate 1mg/ml Solution for Injection or Infusion (Pfizer Healthcare Ireland Unlimited Company). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Vincristine shortage?

Not in the lists we track: Vincristine has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Vincristine works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Vincristine works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Vincristine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Vincristine clinical trials